Peptides
KPV
Also called Lys-Pro-Val
People usually look at KPV for gut comfort, irritated skin or inflammation, often alongside BPC-157. Oral products are marketed for gut-focused goals. That interest comes from promising cell and mouse work; it is not yet a demonstrated treatment for IBS, Crohn’s disease or ulcerative colitis in people.
Dosage & duration
BHRC’s published oral example · reported-use context
Gut-focused oral row
Reported use · unapproved regimen- Dose
- 500 mcg–1 mg total per day
- How often
- Daily oral amount; split not specified in that row
- How long
- The guide discusses about 8 weeks, then a break
The course discussion is separate from its oral-dose row and is not validated for that route. This is a clinic guide, not a trial-proven IBD regimen.
Sources: 3
Keep the total daily amount distinct from the amount in each capsule. A fasting instruction in a commercial guide is not proof of better clinical results.
Gut and skin interest
Comfort is the goal; relief is still unproven
-
Gut comfort
People hope for less pain and more manageable bowel symptoms; cell and mouse results do not establish relief in people.
-
Calmer skin
Skin products raise a separate question, with different formulas and delivery from oral products or injections.
Why does KPV come up in gut discussions?
The attraction is a peptide that might calm inflammatory signaling where gut symptoms occur. The original work showed effects in cells and mice with experimentally induced colitis. It did not enroll people with IBS or inflammatory bowel disease, so it cannot predict symptom relief or remission.
Oral or injectable?
Oral use is often marketed for the gut; injections are marketed for wider inflammation. Those descriptions are not a head-to-head result. A capsule, a skin preparation and an injection have different delivery questions. The relative timing plot cannot tell you the amount acting on the gut lining.
KPV with BPC-157
The pairing is easy to find in marketing, but two plausible ingredients do not establish a better treatment. A blend makes it harder to identify which ingredient, another treatment or normal symptom variation explains a change. Check each ingredient amount instead of treating the combined vial total as a KPV dose.
What would count as useful improvement?
For gut symptoms, the relevant outcomes are things such as pain, bowel frequency and function—not a claim about an inflammatory switch. Persistent bleeding, weight loss or worsening symptoms needs medical assessment rather than repeatedly changing peptide amounts.
Model details: KPV · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 0.48 h is not established by the transporter or mouse efficacy study.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.48 hours
- Absorption half-life assumed
- 0.12 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Cell-culture nanomolar efficacy and PepT1 uptake kinetics are not plasma concentration-time parameters.
- Oral mouse exposure cannot establish human SC F.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Legacy 0.48 h is not established by the transporter or mouse efficacy study.
kpv-relative-timing-2026-10 · version 1
Common questions
Does oral KPV heal leaky gut?
That phrase appears in marketing, but the reviewed work does not establish a human KPV treatment for a diagnosed gut condition. Animal colitis findings cannot predict a personal response.
Is injecting KPV stronger than taking it orally?
There is no verified human comparison establishing that. The best route cannot be inferred from a relative timing plot or a mouse oral experiment.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- Bowel symptoms and skin irritation are different problems, even when both are called inflammation.
- Oral vs injection
- Mouse oral work does not establish the best human route.
- Compared with BPC-157
- A combination has not been shown to improve gut outcomes over either ingredient alone.
- 1. Dalmasso et al.: KPV and intestinal inflammation
Original abstract inspected: human cells and mouse colitis; oral mouse intervention, not a human treatment trial.
- 2. FDA KPV review
2026 scientific review inspected; no human administration/PK evidence identified.
- 3. BHRC: KPV dosage guide
Clinic’s own guide inspected for reported use: oral 500 mcg–1 mg/day; injection and topical examples differ. Clinical benefit and safety assertions not adopted.
- 4. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Legacy 0.48 h is not established by the transporter or mouse efficacy study.
Related compounds and examples
Related compounds
Thymosin Alpha-1
Thymosin Alpha-1: immune-support claims, Zadaxin doses and why the illness being treated matters.
LL-37 (Cathelicidin)
LL-37 for immune, gut and wound-healing questions: what people seek, reported injection amounts and what topical human trials actually found.
Thymalin
Thymalin for immune support and healthy-aging questions: the reported short course, product differences and what the clinical study can tell you.
Protocols featuring KPV
Skin GLOW Stack
Comprehensive skin-and-recovery blend (GHK-Cu + TB-500 + BPC-157 + KPV) dosed daily for collagen, healing, and anti-inflammatory support. Based on the GLOW/Upgraded-Glow blend ratios.
Comprehensive Healing Blend (4-Peptide)
Long-course healing + recovery blend (TB-500 + BPC-157 + KPV + GHK-Cu) dosed daily. A 2-week intro at half dose to assess tolerance, then 10 weeks at the standard dose. Modeled on documented blend ratios.